BOT basically looking at Sofdra being the leading treatment for H/h in the U.S and obtain @ 50% of the market of H/h existing patients initially. Around 1.8 mill patients.(x monthly treatments x. x.????)= $$$$
Sofdra has meet the primary endpoints with unmatched safety & efficacy, with 9/10 patient having a "clinically meaningful experience".
Also superfast turnaround of product to patient, (2-4days)
1% of market to give us @ $300 mill revenue.. 50% would be.............................$
Ann: Botanix Commercial Day Webinar Presentation, page-53
-
- There are more pages in this discussion • 144 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.5¢ |
Change
0.015(3.75%) |
Mkt cap ! $751.1M | |||
| Open | High | Low | Value | Volume |
| 39.5¢ | 42.8¢ | 39.3¢ | $5.876M | 14.27M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 252500 | 41.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 41.5¢ | 78414 | 1 |
View Market Depth
| Last trade - 16.10pm 02/09/2024 (20 minute delay) ? |
| BOT (ASX) Chart |